Four lessons from global health drug discovery: medicine for an ailing industry?
- PMID: 24900531
- PMCID: PMC4025862
- DOI: 10.1021/ml3002105
Four lessons from global health drug discovery: medicine for an ailing industry?
Abstract
In recent years, the pharmaceutical industry has faced many challenges to its business model, undergoing tremendous change and turmoil to survive. Are there any lessons to be drawn from drug discovery focused on Global Health, where there is little market incentive?
Figures
References
-
- Reproduced with permission from:Scannell J. W.; Blanckley A.; Boldon H.; Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Rev. Drug Discovery 2012, 11, 191–200. - PubMed
-
- Payne D. J.; Gwynn M. N.; Holmes D. J.; Pompliano D. L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nature Rev. Drug Discovery 2007, 6, 29–40. - PubMed
-
- Yao F.; MacKenzie R. G. Obesity Drug Update: The Lost Decade?. Pharmaceuticals 2010, 3, 3494–3521.
-
- For more information, go to www.grandchallenges.org/explorations/Pages/introduction.aspx.
LinkOut - more resources
Full Text Sources
